- In January 2024, Amneal announced the launch of a remarkable 39 new retail and injectable products throughout 2023, with 13 of these introduced in the fourth quarter alone. This significant expansion underscores Amneal's commitment to enhancing its product portfolio and meeting market demand. The company’s efforts aim to provide a broader range of therapeutic options for healthcare providers and patients alike
- In January 2024, Kindeva Drug Delivery announced its acquisition of Summit Biosciences, a company known for its expertise in nasal drug development and manufacturing. This strategic move enhances Kindeva's capabilities in the nasal delivery segment, allowing for an expanded product portfolio. The acquisition aims to bolster innovation and meet the growing demand for effective nasal drug therapies
- In January 2022, West announced a significant partnership with Corning to enhance pharmaceutical injectable drug delivery systems. This collaboration aims to leverage both companies' expertise in developing innovative solutions for the safe and efficient delivery of injectable medications. The joint effort is expected to drive advancements in the pharmaceutical industry, improving patient outcomes and streamlining drug administration processes
Frequently Asked Questions
The market is segmented based on Segmentation, By Type (Injectable Drug Delivery Devices, and Injectable Drug Delivery Formulation), Formulation Packaging (Ampoules, Vials, Cartridges, and Bottles), Therapeutic Application (Autoimmune Diseases, Hormonal Disorders, Orphan Diseases, Cancer, and Others), Usage Pattern (Curative Care, Immunization, and Other), Site Of Administration (Skin, Circulatory/Musculoskeletal System, Organs, and Central Nervous System), Distribution Channel (Hospital, and Retail Pharmacy Stores), End User (Hospitals and Clinics, Home Care Settings, and Others) – Industry Trends and Forecast to 2031
.
The Global Injectable Drug Delivery Market size was valued at USD 22.02 USD Billion in 2023.
The Global Injectable Drug Delivery Market is projected to grow at a CAGR of 13.4% during the forecast period of 2024 to 2031.
The major players operating in the market include - Abbott, B.D., Novartis AG, Pfizer , Baxter, Gerresheimer AG, AstraZeneca, Terumo Medical Corporation, Teva Pharmaceutical Industries , Eli Lilly and Company, Schott AG, Sanofi, Johnson & Johnson Private Limited, Mylan N.V., West Pharmaceutical Services , SHL Medical AG, Insulet Corporation, E3D Elcam Drug Delivery Devices, Ypsomed AG, AbbVie , Novo Nordisk A/S-.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America..
